🇺🇸 FDA
Pipeline program

Anti-LeY-CAR-transduced T cells

TMMU-BTC-012

Phase 2 mab active

Quick answer

Anti-LeY-CAR-transduced T cells for Myeloid Malignancies is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Myeloid Malignancies
Phase
Phase 2
Modality
mab
Status
active

Clinical trials